Spirit Scientific Co (ROCO:7790) Debt-to-EBITDA : N/A (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:7790 Spirit Scientific Co Ltd ROCO:7790
26 GF Score
Price NT$48.20
! 3 Warning Signs
View Full Analysis

What is Spirit Scientific Co Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Spirit Scientific Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was NT$6.8 Mil. Spirit Scientific Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was NT$88.4 Mil. Spirit Scientific Co's annualized EBITDA for the quarter that ended in Jun. 2026 was NT$0.0 Mil.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Spirit Scientific Co's Debt-to-EBITDA or its related term are showing as below:

ROCO:7790' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.73   Med: 1.22   Max: 12.99
Current: 4.31

During the past 5 years, the highest Debt-to-EBITDA Ratio of Spirit Scientific Co was 12.99. The lowest was 0.73. And the median was 1.22.

ROCO:7790's Debt-to-EBITDA is ranked worse than
73.53% of 306 companies
in the Biotechnology industry
Industry Median: 1.255 vs ROCO:7790: 4.31

Spirit Scientific Co  (ROCO:7790) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Spirit Scientific Co Debt-to-EBITDA Related Terms

Spirit Scientific Co Debt-to-EBITDA Historical Data

* Premium members only.

The historical data trend for Spirit Scientific Co's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Spirit Scientific Co Debt-to-EBITDA Chart

Spirit Scientific Co Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Debt-to-EBITDA
12.99 1.69 1.22 0.93 0.73

Spirit Scientific Co Quarterly Data
Dec21 Dec22 Dec23 Jun24 Sep24 Dec24 Jun25 Sep25 Dec25 Jun26
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.87 N/A 0.85 1.13 N/A

ROCO:7790 vs VRTX, REGN, MRNA: Debt-to-EBITDA Comparison

For the Biotechnology subindustry, Spirit Scientific Co's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Spirit Scientific Co Debt-to-EBITDA vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Spirit Scientific Co's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Spirit Scientific Co's Debt-to-EBITDA falls into.


ROCO:7790
26GF Score
Spirit Scientific Co Ltd ROCO:7790
Debt-to-EBITDA is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Spirit Scientific Co Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Spirit Scientific Co's Debt-to-EBITDA for the fiscal year that ended in Dec. 2025 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(9.488 + 31.596) / 56.343
=0.73

Spirit Scientific Co's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2026 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(6.844 + 88.361) / 0
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Jun. 2026) EBITDA data.

Spirit Scientific Co Business Description

Address Xintai 5th Road, 19th Floor. No-12, No.93, Section 1, Xizhi District, New Taipei, TWN, 221
Spirit Scientific Co Ltd is engaged in precision regenerative medicine, specializing in platelet cryocrystallization technology and Bio Material Lyophilized Technology (BMLT). The company provides solutions for extracting high-concentration platelet growth factors, enabling safe, flexible, and long-term storage therapies. Spirit Biotech delivers cutting-edge autologous healing reagent preparation services, along with OEM and ODM models. With a focus on unmet medical needs, the company transforms patented technologies into scalable solutions, advancing the future of regenerative healthcare.
26GF Score

Get the complete analysis for ROCO:7790

Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$48.20
Price